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Abstract 
Recent clinical trials using rapalogues in tuberous sclerosis complex (TSC) show regression in volume of 
typically vascularised tumours including angiomyolipomas (AMLs) and sub-ependymal giant cell 
astrocytomas (SEGAs). By blocking mechanistic/mammalian target of rapamycin complex 1 (mTORC1) 
signalling, rapalogue efficacy is likely to occur in part through suppression of hypoxia inducible factors 
(HIFs) and vascular endothelial growth factors (VEGFs). We show that rapamycin reduces HIF-1α protein 
levels, and to a lesser extent VEGF-A levels, in renal cystadenoma cells in a Tsc2+/- mouse model. 
However the precise mechanism(s) underpinning HIF-1α and VEGF-A regulation by mTORC1 are 
uncertain and better delineation of this angiogenic signalling pathway is fundamental for the development 
of therapeutic strategies for vascularised tumours. We establish that mTORC1 drives HIF-1α protein 
accumulation through enhanced transcription of HIF-1α mRNA, a process that is suppressed via inhibition 
of signal transducer and activation of transcription 3 (STAT3). We reveal that STAT3 is directly 
phosphorylated by mTORC1 on Ser727 during hypoxia, promoting HIF-1α mRNA transcription. mTORC1 
also regulates HIF-1α synthesis on a translational level via co-operative regulation of both initiation factor 
4E-binding protein 1 (4E-BP1) and ribosomal protein S6 kinase-1 (S6K1), whilst HIF-1α degradation 
remains unaffected. We therefore propose that mTORC1 drives HIF-1α synthesis in a multi-faceted 
manner through 4E-BP1/eIF4E, S6K1 and STAT3. Interestingly, we observe a disconnect between HIF-
1α protein levels and VEGF-A expression. While both S6K1 and 4E-BP1 regulate HIF-1α translation, 
VEGF-A is primarily under the control of 4E-BP1/eIF4E. S6K1 inhibition reduces HIF-1α but not VEGF-A 
expression, suggesting that mTORC1 mediates VEGF-A expression via both HIF-1α-dependent and -
independent mechanisms. Our work has important implications for the treatment of vascularised tumours, 
where mTORC1 acts as a central mediator of STAT3, HIF-1α, VEGF-A and angiogenesis via multiple 
signalling mechanisms. 
 
Introduction 
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Tumour vascularisation is regulated by hypoxia inducible factor (HIF) proteins. HIFs drive expression of 
over 800 different genes, many of which control cellular processes involved in cancer progression.
1
 As 
well as promoting angiogenesis, HIF activation alters cellular metabolism resulting in enhanced glycolytic 
flux promoting survival under hypoxia.
2
 Inappropriate activation of HIF-1α under normoxia causes a 
metabolic shift towards aerobic glycolysis, driving the Warburg effect which is characteristic of tumour 
cells.
3
 HIFs also promote cell proliferation, survival and metastasis through secretion of growth factors,
4
 
motility and permeability factors
5
 as well as expression of genes involved in the degradation/remodelling 
of the extracellular matrix.
6, 7
 
 HIF is centrally involved in the pathology of a number of inherited diseases where patients are 
predisposed to renal cell carcinoma (RCC) including Von Hippel-Lindau disease (VHL),
8
 Hereditary 
Leiomyomatosis and Renal Cell Cancer (HLRCC),
9
  and Birt-Hogg-Dubé (BHD) syndrome.
10
 In VHL, loss 
of VHL protein function prevents ubiquitin-targeted proteasomal removal of HIF, resulting in inappropriate 
accumulation of HIF protein under normoxia.
11, 12
 Likewise in HLRCC, HIF protein stability is enhanced via 
loss of fumarate hydratase enzyme and a build-up of intracellular fumarate.
9
 In this context, it is known 
that aberrant accumulation of HIF protein drives RCC.  
Tuberous Sclerosis Complex (TSC) is a genetic disorder that predisposes patients to non-malignant 
tumours in multiple organ systems. These include angiomyolipomas (AML) of the kidneys, cutaneous 
angiofibromas, subependymal nodules (SENs) or sub-ependymal giant cell astrocytomas (SEGAs) and 
cortical tubers in the brain, cardiac rhabdomyomas, lymphangioleiomyomatosis (LAM) in the lungs, and 
hamartomas in the eye (see review
13
). TSC-associated tumours are highly vascularised and express 
elevated levels of CD31, a marker of the vascular endothelium, and the angiogenic marker VEGF.
14
 In 
TSC, the major factor driving angiogenesis is thought to be a result of increased signal transduction 
through Rheb and mammalian target of rapamycin complex 1 (mTORC1). Rheb/mTORC1 is normally 
repressed by the TSC:TBC tumour suppressor complex, that is functionally lost in TSC tumours.
15
 Indeed, 
regression of tumour volume is apparent in TSC patients
16, 17
 and mouse models
18
 after mTORC1 
inhibition. Angiogenesis inhibitors have also demonstrated therapeutic benefit and increased survival in 
TSC mouse models.
19
 Given that the anti-angiogenic effects of rapamycin are well established in a variety 
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of diseases,
20-22
 there is a surprising lack of clarity within the literature regarding the mechanisms behind 
mTORC1-mediated angiogenesis.  
 mTORC1 is comprised of the serine/threonine protein kinase mTOR, Lst8 and Raptor. Raptor 
associates with mTORC1 substrates through mTOR signalling (TOS) motifs to facilitate their recruitment 
and phosphorylation.
23
 Inappropriate activation of mTORC1 has been reported in a wide variety of 
malignancies and mTOR inhibitors are currently licensed or undergoing clinical trials for several different 
cancer types.
24
 We previously demonstrated that HIF-1α is modulated by mTORC1, with Rheb over-
expression propagating high levels of HIF transcriptional activity in a rapamycin sensitive fashion.
25
 
Subsequent studies have supported this evidence, however there is a significant degree of conflict within 
the literature regarding the mechanism by which mTORC1 regulates HIF-1α.  For example, Hudson et al. 
showed evidence that HIF-1α stability was reduced by rapamycin but HIF-1α translation and transcription 
were unaffected.26 While Duvel et al. showed evidence that regulation of HIF-1α downstream of mTORC1 
was primarily the result of increased 4E-BP1 phosphorylation and cap-dependent translation.
27
 Tandon et 
al. also demonstrated that mTORC1 regulated the translation of HIF-1α, primarily via S6K1. Where 
shRNA mediated knockdown of S6K1 had comparable affects to rapamycin upon HIF-1α activity in PTEN 
deficient cells.
28
 Active mTORC1 has also been reported to increase HIF-1α mRNA levels in cells devoid 
of TSC2
27, 29
 indicative of transcriptional control. Conversely, a study using human SN12C renal cell 
carcinoma cells with and without VHL indicated that HIF-1α mRNA levels were insensitive to mTOR 
inhibition,
30
 while Treins et al. found that mRNA levels of HIF-1α were not increased with insulin 
stimulation,
31
 suggesting mTORC1 independence.  
 Whilst it is clear that mTORC1 plays a fundamental role in tumour angiogenesis, the mechanisms 
underpinning this are unclear and a complete analysis of these mechanisms is absent from the literature. 
Through various lines of investigation, we systematically challenge a series of potential mechanisms by 
which mTORC1 might regulate HIF-1α. By utilising an array of different assays to explore HIF-1α activity 
and mTORC1 signalling through S6K1, 4E-BP1, and STAT3, we provide evidence that underpins a better 
understanding of how mTORC1 regulates angiogenesis. 
 
Results 
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In Tsc2+/- mice, rapamycin dramatically reduced mTORC1 signalling, HIF-1α and VEGF-A protein 
levels in renal cystadenoma cells 
We previously demonstrated that HIF-1α activity was markedly elevated in TSC2-/- cell lines and 
sensitive to rapamycin inhibition.
25
 We therefore examined the effects of rapamycin on the expression of 
HIF-1α and its gene target VEGF-A in a Tsc2+/- mice model (described here
32
) (Figure 1). These mice 
exhibit reduced TSC2 expression in cystadenomas as demonstrated in Figure 1A.  
12 month old Tsc2+/- mice were treated with 10 mg/kg rapamycin 5 times a week (or vehicle as a 
control) for 2 months. Kidney sections were subjected to immunohistochemical (IHC) analysis to 
determine HIF-1α and VEGF-A protein levels (Figure 1B). Ribosomal protein S6 (rpS6) phosphorylation 
was also analysed as a readout of mTORC1 signalling. As predicted, strong IHC staining of HIF-1α and 
VEGF-A total protein as well as rpS6 phosphorylation was apparent in the cells lining and projecting into 
the lumen of the renal cyst, supporting the involvement of HIF-1α and VEGF-A in TSC pathology. 
Rapamycin potently reduced HIF-1α protein levels (as well as phosphorylation of rpS6), suggesting that 
the anti-tumourigenic effects of rapalogues are in part caused by repression of the mTORC1/HIF-1α 
angiogenic response. VEGF-A expression was also reduced by rapamycin, albeit to a lesser extent. 
Brugaralas et al. previously reported that VEGF-A expression was relatively insensitive to rapamycin in 
cell line models for TSC, we show that this effect also translates to mouse models, suggesting that 
rapalogues may not be fully effective at suppressing VEGF-A expression in TSC patients.
29
 
 
HIF-1α is potently induced by active mTOR mutants  
To explore this mechanism further, we employed cell line models allowing us to manipulate specific facets 
of mTORC1 signalling. We first utilised two constitutively active mTOR mutants; L1460P and E2419K 
(see Figure 2A) originally identified in yeast by Urano et al.
33
 By expressing these active mTOR mutants 
alongside a luciferase reporter vector driven by HIF-1α response elements, we were able to specifically 
examine the effects of mTOR on HIF-1α. As Figure 2B demonstrates, we observed a 3-fold increase in 
HIF-1α activity in cells expressing active mutants compared to wild-type. As mTORC1 activity is 
dependent upon an amino acid input (for review see
34
); and HIF-1α regulation has not been studied in the 
context of amino acid availability, we utilised these mutants to examine the effects of nutrient withdrawal 
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upon HIF-1α. Indeed, nutrient withdrawal potently inhibited HIF-1α activity in cells expressing either wild-
type or the E2419K mutant of mTOR. In concordance with our previous study, HIF-1α activity was also 
partially resistant to amino acid deprivation in cells expressing L1460P.
35
 This result is therefore the first 
direct evidence that amino acids regulate HIF-1α activity via an mTORC1-dependent mechanism. Given 
that HIF-1α activity in cells expressing the L1460P mutant was partially insensitive to nutrient withdrawal, 
it is possible that the L1460P mutant is inappropriately targeted to the lysosomes and could therefore be 
a useful tool for investigating amino acid signalling to mTORC1. Whilst it is clear that mTORC1 mediates 
HIF-1α, it remains unclear how this regulation occurs, figure 2C indicates the possible mechanisms 
underlying this regulation. 
 
Rapamycin does not affect the protein stability of HIF-1α 
We next analysed the effects of rapamycin upon endogenous HIF-1α protein accumulation in HEK293 
cells under hypoxia (Figure 3A). Cycloheximide, which blocks ribosomal translocation, was used as a 
control to prevent de novo protein synthesis of HIF-1α. As Figure 3A indicates, cyclohexamide pre-
treatment is sufficient to completely ablate HIF-1α protein synthesis under hypoxia. As expected, 
rapamycin pre-treatment caused a reduction in HIF-1α protein levels by approximately one third at all time 
points (3A), clearly demonstrating that mTORC1 promotes accumulation of the HIF-1α protein. Hudson et 
al.’s work indicated that rapamycin decreased the stability of HIF-1α,
26
 whereas other groups have 
indicated that rapamycin reduces the synthesis of HIF-1α on a transcriptional or translational level.
26-28
 
Given that we were able to completely block HIF-1α synthesis with cyclohexamide, a pulse-chase 
experiment was performed in hypoxic HEK293 cells in the presence and absence of rapamycin (Figure 
3B) to determine whether HIF-1α stability is affected by rapamycin.  
In the absence of de novo HIF-1α protein synthesis, HIF-1α levels rapidly decreased with a loss 
of approximately 50% of HIF-1α protein after just 5 min. This rapid deterioration of HIF-1α protein may 
suggest residual activity of prolyl-hydroxylase enzymes, even under hypoxia. Importantly, however, 
rapamycin did not impact the half-life of HIF-1α. Furthermore, inhibition of mTOR with the ATP-
competitive inhibitor, KU-0063794, had no additional effect upon the stability of HIF-1α when directly 
compared to rapamycin (data not shown). Densitometry analysis of the three independent experiments 
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further supported this conclusion and is demonstrated in Figure 3C, no significant differences were 
observed between the rapamycin treated and pre-treated samples at any time-points analysed. Our work 
determines that mTORC1 promotes HIF-1α through increased synthesis rather than reduced degradation 
in support of the work by Duvel and Tandon et al.
27, 28
 
 
Both rapamycin and KU-0063794 effectively suppress HIF-1α protein accumulation 
We next analysed HIF-1α protein levels in hypoxic HEK293 cells expressing the active mutant of mTOR 
(E2419K). As predicted, the E2419K mutant induced a greater than 2-fold increase in endogenous HIF-1α 
protein levels after 2 h of hypoxia (Figure 4A), suggesting that during the initial stages of hypoxia, 
mTORC1 activation is crucial for promoting HIF-1α synthesis to elicit the hypoxic response. 
Phosphorylation of 4E-BP1 and rpS6 was analysed to demonstrate upregulation of mTORC1 in the 
presence of the active E2419K mutant. Interestingly, we observed fluctuations in 4E-BP1 Ser65 
phosphorylation under hypoxia, this is likely to  be the result of feedback inhibition to mTORC1 from the 
HIF-1α target REDD1.
36
 rpS6 phosphorylation and HIF-1α protein levels were maintained indicating that 
mTORC1 is not fully suppressed. 
Previous work demonstrates that some substrates of mTORC1 are more robustly inhibited with 
mTOR kinase inhibitors as opposed to rapalogues.
37, 38
 To determine whether mTOR kinase inhibitors 
may be more effective than rapamycin at suppressing HIF-1α, we compared the effects of rapamycin to 
the ATP-competitive KU-0063794 mTOR kinase inhibitor (Figure 4B).
39
 Treatment with KU-0063794 
suppressed Akt phosphorylation at the mTORC2 site (Ser473), as well as reducing rpS6 phosphorylation, 
indicating suppression of both mTOR complexes. Ser65 phosphorylation of 4E-BP1 was partially 
rapamycin insensitive, as has previously been reported.
40
 Interestingly, we observed complete recovery 
of 4E-BP1 phosphorylation during rapamycin treatment after just 2 h. Conversely, Choo et al. indicated 
that this recovery took approximately 6 h, it is therefore likely that over-expression of the active mTOR 
mutant within these cells caused a faster recovery from rapamycin repression.  
mTORC1 inhibition with rapamycin caused a significant suppression in HIF-1α activity as before, 
however, no further inhibition of HIF-1α protein levels was observed with KU-0063794 compared to 
rapamycin. This confirms that mTORC1, rather than mTORC2 is driving the accumulation of HIF-1α 
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protein. Also consistent with previous observations, rapamycin treatment caused a slight increase in Akt 
phosphorylation, which is likely to be a result of reduced negative feedback signalling to IRS-1 via 
S6K1.
41  
 
Active S6K1 promotes HIF-1α protein accumulation 
As depicted in Figure 2C, mTORC1 may promote HIF-1α synthesis via enhanced protein translation. 
S6K1 promotes protein translation through phosphorylation of numerous eukaryotic initiation factors
42-44
 
and may drive HIF-1α protein synthesis in this manner. Tandon et al. reported that S6K1 was essential for 
the translation of HIF-1α,
28
 whereas Duvel et al. showed that S6K1 knockdown had no effect on a 
translational luciferase reporter driven by the HIF 5’UTR.
27
 
To address this conflict and assess the involvement of S6K1 in HIF-1α regulation, we utilised a 
constitutively active S6K1 mutant (F5A-E389-R3A see Figure 5A). F5A-E389-R3A contains a mutation 
within the mTORC1 signalling (TOS) motif, a triple mutation to the ‘RSPRR’ motif which is acts as an 
mTORC1-mediated auto-inhibitory domain, as well as an E389 phospho-mimetic mutation within the 
linker region of S6K1. This F5A-E389-R3A mutant therefore drives a constitutively high level of S6K1 
activity in cells regardless of mTORC1 activity.
45
 HEK293 cells were transfected with either pRK7 or HA-
S6K1-F5A-E389-R3A and cultured under hypoxia, HIF-1α protein accumulation was determined over a 4 
h time-course. Expression of the active S6K1 mutant caused an approximate 2-fold increase in HIF-1α 
protein when compared to empty vector (Figure 5B). Conversely, the impact upon VEGF-A expression 
was not as dramatic, with the active S6K1 mutant causing only a slight increase in protein levels of 
VEGF-A. To confirm this effect, HEK293 cells were treated for 1 h prior to hypoxic incubation with the 
highly specific S6K1 inhibitor, PF-4708671.
46
 As Figure 5D demonstrates, HIF-1α protein levels were 
highly sensitive to S6K1 inhibition, however VEGF-A expression levels were maintained despite the drop 
in HIF-1α protein. This suggests that VEGF-A expression is mediated via both HIF-1α-dependent and -
independent mechanisms, as has previously been reported within the literature.
47
  
In order to determine whether S6K1 modulated HIF-1α expression on a transcriptional and/or 
translational level, HIF-1α mRNA levels were also examined. Figure 5D demonstrates that HIF-1α mRNA 
levels are unaffected by either expression of the active S6K1 mutant or inhibition of S6K1 with PF-
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4708671, indicating that S6K1 mediates HIF-1α protein expression solely through protein translation. 
Interestingly, PF-4708671 acted as a dominant inhibitor of HIF-1α, reducing HIF-1α protein expression to 
a level lower than cells expressing empty vector, even in the absence of insulin stimulation. PF-4708671 
also caused an increase in S6K1 Thr389 phosphorylation, as previously reported.
46
 
 
eIF4E availability is a rate limiting factor in the synthesis of both HIF-1α and VEGF-A 
We next assessed 4E-BP1's role as a negative regulator of HIF-1α through inhibition of eIF4E. eIF4E 
availability is considered a rate-limiting factor of 5’-cap-dependent translation downstream of mTORC1.
48
 
Duvel et al. showed evidence that 4E-BP1 represses HIF-1α by acting as a negative regulator of eIF4E,
27
 
in contrast to Hudson et al. who observed no effects on HIF-1α translation with rapamycin treatment.
26
 To 
examine whether inhibition of eIF4E could modulate HIF-1α activity, TSC2-/- MEFs, which exhibit 
constitutively active mTORC1 signalling, were transfected with the HIF-1α luciferase reporter alongside 
mutant or wild-type 4E-BP1 and cultured under hypoxia. Two mutants of 4E-BP1 were utilised; 4E-
BP1(F114A), which contains a mutation within the TOS motif (so cannot be phosphorylated by mTORC1 
and dominantly inhibits eIF4E), and the Y54A/L59A mutant which contains mutations within the eIF4E-
binding domain. The 4E-BP1 Y54A/L59A mutant serves as a negative control as it is unable to interact 
with eIF4E. As expected; 4E-BP1(F114A) was less phosphorylated and consequently bound more avidly 
to eIF4E when compared to wild-type 4E-BP1 (Figure 6A). The 4E-BP1(F114A) TOS mutant, which 
potently bound to eIF4E, repressed the activity of HIF-1α by approximately one third compared with the 
wild-type (35 ±2%). In contrast, both the Y54A/L59A mutant and wild-type 4E-BP1 had minimal effects 
upon HIF-1α activity. The 4E-BP1(F114A) TOS-mutant was also able to suppress HIF-1α protein 
accumulation in the HEK293 cells, as demonstrated by the hypoxic time course in Figure 6C. There was 
an approximate 50% reduction in HIF-1α protein levels after 2 h of hypoxia in cells expressing 4E-
BP1(F114A). This result implies that mTORC1 mediated phosphorylation of 4E-BP1 is a critical factor 
driving HIF-1α protein synthesis. In contrast to the effects of S6K1 inhibition, expression of the 4E-BP1-
F114A mutant caused a significant reduction in VEGF-A expression (Figure 6C), indicating that 
repression of 4E-BP1 by mTORC1 is crucial for the VEGF-A response. HIF-1α mRNA levels were 
unaffected by expression of the 4E-BP1-F114A mutant (Figure 6D), suggesting that, in a manner 
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analogous to S6K1, this regulation is also on a translational level. This data suggests that mTORC1 
mediates HIF-1α activity by promoting 5’-cap-dependent translation through both 4E-BP1/eIF4E and 
S6K1, while the translation of VEGF-A is primarily regulated by 4E-BP1/eIF4E and not S6K1.  
 
mTORC1 drives the transcription of HIF-1α via STAT3 
To further investigate mTORC1 involvement in HIF-1α mRNA transcription, HEK293 cells were 
transfected with the active mTOR(E2491K) mutant and insulin stimulated (to promote maximal activation 
of mTORC1) in the presence or absence of rapamycin. Q-PCR analysis revealed a substantial rapamycin 
sensitive increase in HIF-1α mRNA levels in response to insulin, indicating a transcriptional facet of 
control through mTORC1 (Figure 7A). Although elevation of HIF-1α mRNA levels has been previously 
reported within TSC2-/- MEFs,
27, 29
 the mechanism driving HIF-1α mRNA transcription downstream of 
mTORC1 is unknown. We hypothesised that another downstream signalling target of mTORC1 may be 
involved in this regulation. Previous work in tumour cells reported links between HIF-1α and STAT3.
49
 
Furthermore, Yokogami et al. suggested a link between mTORC1 and STAT3, demonstrating 
phosphorylation of a C-terminal STAT3 peptide using a crude in vitro mTOR kinase assay.
50
 Other 
studies have shown upregulation of STAT3 signalling in cell line models for TSC,
51, 52
 however the direct 
phosphorylation of STAT3 by mTORC1 has yet to be confirmed. The mTOR kinase assay employed by 
Yokogami et al. was not optimal; for instance, a short STAT3 peptide (which did not contain any potential 
Raptor interacting motifs for substrate recognition) was assayed alongside over-expressed mTOR in the 
absence of Raptor, using MnCl2
 
and high ATP levels to artificially enhance kinase activity. We therefore 
utilised our previously optimised mTORC1 specific kinase assay,
35
 with more physiologically relevant 
assay conditions to verify whether full length recombinant STAT3 was indeed a direct substrate for 
mTORC1 (7B). As Figure 7B shows; we observe robust phosphorylation of STAT3 at Ser727 by 
mTORC1. Inclusion of purified recombinant GTP-loaded GST-Rheb, a potent and specific activator of 
mTORC1, increased Ser727 phosphorylation of STAT3 in a manner similar to the well characterised 
mTORC1 substrate; 4E-BP1. This data confirms that STAT3 is a direct mTORC1 target. 
To determine whether STAT3 was involved in HIF-1α mRNA expression, HEK293 cells were pre-
treated with either rapamycin, or STAT3 inhibitors: FLLL31 (an upstream JAK2 inhibitor) and 5,15-
11 
 
diphenylporphyrin (5,15,DPP), an Src homology-2 domain (SH2) antagonist (Figure 7D) in the presence 
of insulin. CNTF (ciliary neurotrophic factor) was also utilised to stimulate STAT3 Tyr705 phosphorylation 
as this is considered to be a priming event required for Ser727 phosphorylation by mTORC1.
53
 In a 
manner analogous to rapamycin treatment, inhibition of STAT3 potently blocked insulin induced HIF-1α 
mRNA induction. This result suggests that the mechanism by which mTORC1 promotes HIF-1α mRNA 
expression is via phosphorylation of STAT3 at Ser727. HIF-1α protein levels were also examined to verify 
this finding. As Figure 7D indicates, both STAT3 inhibitors suppressed HIF-1α protein levels, further 
supporting the conclusion that STAT3 drives HIF-1α transcription. Intriguingly, the curcumin analog, 
FLLL31, had a dramatic dominant inhibitory effect on HIF-1α, reducing expression levels by 
approximately 80%. In contrast, both rapamycin and 5,15,DPP treatment both resulted in an approximate 
30% reduction in HIF-1α expression. Analysis of rpS6, 4E-BP1 and STAT3 Tyr705 phosphorylation in 
these cells revealed that this was due to dual suppression of both JAK/STAT and mTORC1 signalling by 
FLLL31. This dual repression of both signalling pathways makes FLLL31 an ideal potential therapeutic for 
the treatment of vascularised tumours where mTORC1 is active.  
 
Discussion 
Although mTORC1 is known to potently activate HIF-1α,
25
 the mechanism(s) governing this regulation are 
poorly defined. We designed this study to systematically examine specific facets of mTORC1 mediated 
angiogenesis to better understand this process. Although previous studies have suggested roles for either 
S6K1 or 4E-BP1 in driving HIF-1α activity, few studies have investigated the effects of both. We have 
used a variety of methodologies to characterise angiogenic signalling downstream of mTORC1 and show 
for the first time that both 4E-BP1 and S6K1 promote the translation of HIF-1α.  
Furthermore, we confirm previous reports that mTORC1 drives HIF-1α translation and uncover 
the mechanism by which this occurs. We show that mTORC1 promotes the phosphorylation of STAT3 at 
Ser727 during hypoxia to promote HIF-1α transcription, and that STAT3 inhibition effectively represses 
insulin induced HIF-1α transcription in a similar manner to rapamycin. 
Previous studies identified putative hypoxia response elements (HREs) in the HIF-1α promoter, 
suggesting an auto-regulatory loop whereby HIF-1α may up-regulate synthesis of its own mRNA.
54
 This is 
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unlikely as expression of the S6K1 and 4E-BP1 mutants caused substantial effects on HIF-1α protein but 
not mRNA levels. We show that HIF-1α mRNA levels are suppressed with mTORC1/STAT3 inhibition and 
conclude that mTORC1 mediates HIF-1α transcription via STAT3, confirming STAT3 as direct substrate 
for mTORC1. Like HIF-1α; STAT3 mediates several cellular processes linked with cancer progression 
including cellular survival, proliferation and metastasis.
55, 56
 It is likely that upregulation of STAT3 
contributes to the pathology of TSC-associated hamartomas and cancer progression in tumours where 
mTORC1 is active.  
Previous studies demonstrated upregulation of STAT3 Tyr705 phosphorylation in mouse/cell line 
models for TSC.
51, 52
 Conversely, our results indicate that Tyr705 phosphorylation is insensitive to 
rapamycin inhibition. This may suggest that STAT3 Tyr705 phosphorylation is upregulated as a result of 
disrupted feedback mechanisms due to prolonged mTORC1 activation in the TSC models.  
Importantly, we demonstrate that the STAT3 inhibitor FLLL31 has significant inhibitory effects on 
HIF-1α transcription and translation, through dual suppression of both mTORC1 and STAT3 signalling 
pathways. FLLL31 may therefore be a more appealing drug for the treatment of vascularised tumours, 
with greater therapeutic benefit than mTORC1 or STAT3 inhibitors alone. 
It is well documented that VHL mediates proteasomal degradation of HIF-1α under normoxia.
11
 
However, VHL and oxygen independent mechanisms of HIF-1α degradation have also been reported.
57
 
Hudson et al. showed evidence that rapamycin influences the stability of HIF-1α, while the transcription 
and translation are unaffected.
26
 We show contrasting evidence in multiple experiments (Figures 5, 6 and 
7) that both HIF-1α translation and transcription are subject to modification by mTORC1, in concordance 
with other studies examining HIF-1α synthesis.
27, 31, 58
 Furthermore, we observe no difference in the half-
life of HIF-1α protein in rapamycin treated and untreated cells. We therefore conclude that mTORC1 
regulates the synthesis of HIF-1α (via both mRNA transcription and protein translation) whilst VHL 
mediates HIF-1α protein turnover (see figure 8).  
S6K1 regulates a number of translation initiation factors, including eIF3,
42
 eIF4B,
59
 and elongation 
factor 2 kinase (eEF2k)
60
 and may enhance HIF-1α translation via these substrates. The specific S6K1 
inhibitor had a dramatic impact on HIF-1α protein levels whilst HIF-1α mRNA levels were maintained; 
indicating that S6K1 promotes HIF-1α translation but not its transcription. Interestingly, VEGF-A levels 
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were insensitive to inhibition or activation of S6K1, while expression of the dominant inhibitory 4E-BP1 
mutant had a dramatic impact upon VEGF-A levels. This indicates that mTORC1/4E-BP1 signalling drives 
VEGF-A expression via both HIF-1α-dependent and -independent mechanisms. Given that rapamycin is 
known to cause incomplete suppression of eIF4E,
40
 this  finding explains why VEGF-A levels in the Tsc2-
/+ mice are less sensitive to rapamycin inhibition than HIF-1α and phospho-rpS6 levels. Our data 
suggests that in the treatment of vascularised tumours, targeting eIF4E in combination with rapamycin 
may be a more effective strategy for reducing VEGF-A expression. 
Previous work by Thomas et al. suggested that HIF-1α may be preferentially translated downstream 
of mTORC1 as a TOP (tract of pyrimidine) mRNA.
30
 Two recent studies used ribosomal profiling to 
produce a unified model for 5’-TOP mRNA translation. These studies demonstrated that mTORC1 
promotes the translation of TOP mRNAs via 4E-BP1 phosphorylation and eIF4E availability.
61, 62
 Given 
that we observed S6K1 involvement in HIF-1α activity, as well as an mTORC1-dependent STAT3 input 
into HIF-1α mRNA transcription, it is likely that the rate of HIF-1α translation is proportional to the 
abundance of HIF-1α mRNA, rather than any selective qualities conferred by its mRNA structure. This is 
in concordance with current thinking that HIF-1α is not a genuine 5’-TOP mRNA.
63
 
Our findings suggest that STAT3, 4E-BP1, and S6K1 act in concert to drive the angiogenic response 
through mTORC1. Placing mTORC1 as a central mediator of the hypoxic response via multiple signalling 
outputs; Figure 8 indicates the different mechanisms delineated within this study. Recent evidence has 
suggested that mRNAs translated by mTORC1 are regulated via eIF4E availability, and can be stratified 
into functional groups controlling oncogenic processes including cell proliferation, metabolism and 
invasion.
62
 We show evidence that not all the oncogenic signalling outputs downstream of mTORC1 are 
mediated solely by eIF4E availability, and that both S6K1 and 4E-BP1 facilitate the angiogenic response 
at a translational level.  
 
Materials and Methods 
Animal treatment and Immunohistochemistry (IHC) 
Animal procedures were performed in accordance with the UK Home Office guidelines and approved by 
the Ethical Review Group of Cardiff University. Tsc2+/- mice (described here
32
) were treated with 10 
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mg/kg rapamycin/vehicle via intra-peritoneal injection 5 times a week for 2 months. Animals were 
humanely killed and kidney sections prepared for IHC analysis. Antibodies against HIF-1α, VEGF-A and 
phosphorylated rpS6 (S6 p-S235/236) (Cell Signalling Technology, Danvers, USA) were used for IHC. 
SignalStain Boost Rabbit specific IHC Detection Reagent (Cell Signalling Technology) was used for 
antigen staining. Briefly, paraffin-embedded mouse kidney sections were deparaffinised and rehydrated. 
Sections were boiled for 10 min in 10 mM sodium citrate buffer (pH 6.0). After 3 washes in TBST, 
sections were blocked in 1.5% (v/v) goat serum for 10 min at room temperature. Antigen staining was 
performed according to manufacturer’s protocol. 
 
Plasmid details 
Myc-mTOR and active mutant constructs,
35
 HA-S6K1 constructs
45
 and 4E-BP1 constructs
68
 are described 
previously. The HIF-1α specific inducible luciferase reporter construct was purchased from Affymetrix Inc. 
(Vignate-Milano, Italy). Gateway recombination cloning technology (Life Technologies) was utilised to 
generate GST-STAT3 from an I.M.A.G.E. clone (purchased from ATCC, Manassas), in accordance with 
manufacturer’s guidelines. 
 
Antibodies and biochemicals 
Anti-myc, anti-rpS6 phospho-Ser235/236, anti-eIF4E, anti-4E-BP1 phospho-Thr70, anti-STAT3 Ser727 
and Tyr705, and anti-β-actin antibodies were obtained from Cell Signalling Technology. Anti-Rheb was 
obtained from Santa Cruz (Heidelberg, Germany), anti-HA was obtained from Roche (Hertfordshire, UK), 
and Anti-HIF-1α was obtained from BD transduction laboratories (Oxford, UK). Rapamycin was obtained 
from Calbiochem (Nottingham, UK). Dimethyloxallyl Glycine (DMOG) was purchased from R & D systems 
(Minneapolis, USA). KU-0063794 was purchased from Chemquest Ltd. (Cheshire, UK). Cycloheximide, 
insulin, PF-4708671, 5,15-DPP, FLLL31 and all other general lab chemicals were obtained from Sigma-
Aldrich (Dorset, UK) unless otherwise stated. 
 
Cell Culture and transfection 
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HEK293s, TSC2-/- and TSC2+/+ MEFs (a kind gift from Prof. D. Kwiatkowski, Harvard University, Boston) 
were cultured in Dulbecco’s Modified Eagle's Medium (DMEM) supplemented with 10% (v/v) foetal calf 
serum and 100 µ/ml penicillin streptomycin (Life Technologies). Transfections were carried out using 
Lipofectamine 2000 in accordance with manufacturer’s protocol (Life Technologies).  
 
Time course experiments 
HEK293 cells were transfected, drug treated as indicated and placed into a Binder CB150 hypoxic 
chamber set at 1 % O2 for the indicated time points. Cells were lysed directly in sample buffer (62.5 mM 
Tris HCL, 50 mM DTT, 2 % SDS (w/v), 10 % Glycerol (w/v), 0.1 % Bromophenol blue (w/v) pH 7.6) and 
sonicated for 5 x 20 s cycles on full power (30 amplitude microns)  before analysis by western blotting. 
 
Western Blotting 
Lysates were resolved by SDS-PAGE and proteins were transferred to polyvinylidene difluoride 
membranes (Millipore, Edinburgh, UK). Membranes were blocked in 5 % (w/v) dry milk powder dissolved 
in Tris-buffered saline containing 0.1 % (v/v) Tween, then probed with primary antibody and horse radish 
peroxidase-conjugated secondary antibody (Sigma-Aldrich). Proteins were visualized using Enhanced 
Chemiluminescent solution and Hyperfilm (both GE Healthcare, Buckinghamshire, UK). All western blots 
are representative of at least three independent experiments. Where densitometry analysis is shown, 
imageJ 1.43v software was utilised to determine relative levels of HIF-1α, standardising the untreated 
control sample to 1 after either 1 or 2 h in hypoxia. 
 
Luciferase Assays 
These assays were carried out as described previously,
35, 69
 using the HIF-1α specific luciferase reporter 
construct (Affymetrix Inc.) and Promega dual-luciferase reporter assay system in accordance with 
manufacturer’s protocol (Promega, Southampton, UK).  
 
 
mTORC1 kinase assays 
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Kinase assays were carried out as previously described.
35
 Recombinant GST-STAT3 was purified from 
rapamycin treated HEK293 cells and assayed in the presence and absence of 75 ng purified GST-Rheb 
for 1 h at 30
o
C with gentle agitation.  
 
Quantitative PCR 
Q-PCR was performed as previously described.
10
 Primer sets for HIF-1α (cat no. QT01039542) and β-
actin (cat no. QT01680476) were purchased from Qiagen who retain the right to withhold primer 
sequence information. Fold change was calculated using the ddCT (delta-delta-Ct) method, standardised 
to β-actin. A dissociation step was performed to verify a single product was produced with each primer 
set. The size of PCR products was also verified by resolution on a 2% polyacrylamide gel with both HIF-
1α and β-actin giving an approximate amplicon length of 104 bp. All Q-PCR primer assays in this study 
were at least 96% efficient. 
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Figure Legends 
Figure 1: In Tsc2+/- mice, rapamycin reduced mTORC1 signalling, HIF-1α and VEGF protein levels 
in renal cystadenoma cells lacking functional Tsc2 
A: Paraffin-embedded kidney sections from five 12 month old Tsc2
+/–
 mice were analysed by IHC. Thirty 
five cystadenomas were analysed for Tsc2 expression. Tsc2 expression was either undetectable or 
markedly reduced within these lesions. B: Tsc2
+/–
 mice of 12 months old were treated with 10 mg/kg 
rapamycin (n=4) or vehicle (n=4) for two months. Paraffin-embedded kidney sections were stained using 
IHC with an antibody against pS6 (Ser235/236), HIF-1α or VEGF-A. Thirty renal lesions were scored for 
each treatment group. All lesions from mice treated with rapamycin showed a significant reduction in 
phosphor-rpS6 and HIF-1α. VEGF was also reduced by rapamycin treatment although to a lesser extent.  
Figure 2: HIF-1α is potently induced by active mTOR mutants. 
A: mTOR schematic indicating conserved regions and mutation positions. Domains: FRB refers to 
FKBP12/Rapamycin binding domain, NRD: Negative regulatory domain. B: HEK293 cells transfected with 
the mTOR mutants as indicated in conjunction with the HIF-1α inducible luciferase reporter. Cells were 
starved of amino acids (AA) and cultured in media containing 1 mM DMOG (to mimic hypoxia) for 4 h. 
Cells were stimulated with 10 µg/ml insulin 15 min prior to lysis. Luminescence was measured and 
standardised to total protein as determined by a Bradford assay. Error bars indicate standard deviation 
between three independent experiments. C: mTORC1 may be able to regulate the synthesis, degradation 
or activity of HIF-1α. There are several different ways in which this may occur; dotted lines indicate 
potential mechanisms of regulation whilst solid lines indicate known facets of the pathway.  
Figure 3: Rapamycin does not affect the protein stability of HIF-1α 
A: HEK293 cells were treated with vehicle, 10 µg/ml cyclohexamide or 50 nM rapamycin for 30 min prior 
to hypoxic incubation for the given time points. B: HEK293 cells were cultured under hypoxia for 2 h to 
allow build-up of HIF-1α protein then pre-treated with 50 nM rapamycin or vehicle for 30 min. 10 µg/ml 
cycloheximide was added to the cells before hypoxic incubation for the given time points. Lysates were 
sonicated and analysed for HIF-1α and β-actin protein levels using western blotting. C: HIF-1α protein 
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levels from Figure 3B were analysed using densitometry. Data was collated from three individually 
repeated experiments and analysed for statistical significance. No difference in the half-life of HIF-1α was 
observed between the rapamycin treated and untreated samples.    
Figure 4: Both rapamycin and KU-0063794 effectively suppress HIF-1α protein accumulation 
A: HEK293 cells were transfected with wild-type or the active mutant of mTOR (E2419K) then placed into 
the hypoxic chamber for the given time points. Lysates were sonicated and analysed for HIF-1α protein 
levels, as well as phosphorylated and total 4E-BP1 and rpS6 to indicate mTORC1 activity. Result is 
representative of three independent replicated experiments. B: HEK293 cells expressing the active 
mutant were treated with 50 nM rapamycin (rap) or 1 µM KU-0063794 (KU) for 1 h prior to hypoxic 
exposure and a time course was performed as described in 4A. Akt phosphorylation was used as a 
readout for mTORC2 activity whilst phospho-rpS6 and phospho-4E-BP1 were used as indicators of 
mTORC1 activity. 
Figure 5: Active S6K1 promotes HIF-1α protein accumulation 
A: Schematic showing mutant constructs of S6K1 utilised, indicating conserved domains and mutated 
regions. B: HEK293s were transfected with either pRK7 or HA-S6K1-F5A-R3A-E389 and subjected to 
hypoxia for the given time points prior to lysis. HIF-1α protein levels were quantified using western blotting 
and imageJ software for densitometry analysis. Result is representative of three independent 
experiments. C: Untransfected HEK293 cells were treated for 1 h with 10 µM PF-4708671 and 15 min 
with 10  μg/ml insulin prior to 4 h hypoxic/normoxic incubation. Cells were lysed directly in sample buffer, 
sonicated and analysed for protein levels using western blotting. Densitometry analysis was performed 
using imageJ software. D: Duplicate HEK293 cells expressing either empty vector, wild-type of active 
S6K1 mutant were treated with vehicle or 10 µM PF-4708671 as indicated and incubated in the hypoxic 
chamber for 1 hr. mRNA was extracted from half the lysates and Q-PCR was performed to determine 
HIF-1α mRNA levels, standardised to β-actin. The remaining lysates were sonicated and analysed by 
western blotting for HIF-1α expression and S6K1 activity. 
 
Figure 6: eIF4E availability is a rate limiting factor in the synthesis of HIF-1α and VEGF 
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A & B: TSC2-/- MEFs were transfected with either pACATG-2 or mutant constructs of 4E-BP1 alongside 
the HIF-1α luciferase reporter. Lysates were analysed for HIF-1α induced luciferase activity (standardised 
to total protein levels). Graph indicates results from three independent experiments. eIF4E was 
immunoprecipitated from the remainder of the lysates cells using m
7
GTP beads and 4E-BP1 binding was 
assessed using western blotting. C: The TOS-mutant of 4E-BP1 was over-expressed in HEK293 cells 
cultured under hypoxia for the given time points. Lysates were analysed for total HIF-1α and VEGF levels 
using western blotting. D: HEK293 cells expressing empty vector/4E-BP1 mutant were cultured under 
hypoxia for 4 h, mRNA was extracted from the total lysates and Q-PCR was performed to determine HIF-
1α mRNA levels (standardised to β-actin). 
Figure 7: mTORC1 drives the transcription of HIF-1α via STAT3  
A: HEK293 cells expressing empty vector or the active mutant of mTOR were cultured under hypoxia in 
the presence of insulin and or rapamycin as indicated. mRNA was extracted from total lysates, HIF-1α 
mRNA was quantified as standardised to β-actin. B: mTORC1 kinase assay: An active mTORC1 complex 
was purified from insulin stimulated HEK293 cells grown under serum-starved conditions as described, 
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GST-STAT3 and GST-4E-BP1 were purified from serum-starved HEK293 cells, as was GST-Rheb, which 
was then loaded with GTPγS. Purified mTORC1 complex was incubated alongside potential substrates 
with and without GTPγS-Rheb (as indicated) for 1 h at 30
o
C with gentle agitation. SDS-PAGE and 
western blotting with phospho-specific antibodies was utilised to determine specific phosphorylation 
events as well as mTOR/Raptor purification. C: Untransfected HEK293 cells were treated with 
rapamycin/STAT3 inhibitors for 45 min prior to 30 min of insulin/CNTF stimulation (as indicated). mRNA 
was extracted from total lysates and quantified as above (7A). D: HEK293 cells were pre-treated with 
STAT3 inhibitors 5 nM FLLL31, 50 nM 5,15,DPP or vehicle for 30 mins, then stimulated with 25 ng/ml 
CNTF (to stimulate STAT3 Tyr705 phosphorylation) and insulin (to stimulate mTORC1 activation) before 
1 h incubation under hypoxia. Lysates were sonicated and analysed using western blotting. ImageJ 
software was utilised to analyse HIF-1α protein levels via densitometry.  
Figure 8: mTORC1 mediated angiogenesis 
Schematic showing multiple mTORC1 inputs into angiogenesis. As demonstrated in this study, mTORC1 
regulates the translation of HIF-1α via both 4E-BP1/eIF4E and S6K1. Although S6K1 can also promote 
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HIF-1α translation, VEGF-A does not appear to be directly affected by active S6K1. mTORC1 also 
controls the transcription of HIF-1α mRNA in a rapamycin sensitive fashion via STAT3 phosphorylation, 
indicating that mTORC1 mediates angiogenesis via three distinct mechanisms. 
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